Skip to main content

01-18-2017 | Diabetes prevention | Review | Article

Diabetes and its drivers: the largest epidemic in human history?

Journal: Clinical Diabetes and Endocrinology

Author: Paul Z. Zimmet

Publisher: BioMed Central


The “Diabesity” epidemic (obesity and type 2 diabetes) is likely to be the biggest epidemic in human history. Diabetes has been seriously underrated as a global public health issue and the world can no longer ignore “the rise and rise” of type 2 diabetes. Currently, most of the national and global diabetes estimates come from the IDF Atlas. These estimates have significant limitations from a public health perspective. It is apparent that the IDF have consistently underestimated the global burden. More reliable estimates of the future burden of diabetes are urgently needed.
To prevent type 2 diabetes, a better understanding of the drivers of the epidemic is needed. While for years, there has been comprehensive attention to the “traditional” risk factors for type 2 diabetes i.e., genes, lifestyle and behavioral change, the spotlight is turning to the impact of the intra-uterine environment and epigenetics on future risk in adult life. It highlights the urgency for discovering novel approaches to prevention focusing on maternal and child health. Diabetes risk through epigenetic changes can be transmitted inter-generationally thus creating a vicious cycle that will continue to feed the diabetes epidemic. History provides important lessons and there are lessons to learn from major catastrophic events such as the Dutch Winter Hunger and Chinese famines. The Chinese famine may have been the trigger for what may be viewed as a diabetes “avalanche” many decades later. The drivers of the epidemic are indeed genes and environment but they are now joined by deleterious early life events. Looking to the future there is the potential scenario of future new “hot spots” for type 2 diabetes in regions e.g., the Horn of Africa, now experiencing droughts and famine. This is likely to occur should improved economic and living conditions occur over the next few decades. Type 2 diabetes will remain one of the greatest challenges to human health for many years to come.
Benedictow OJ. The black death, 1346–1353: the complete history. Woodbridge: The Boydell Press; 2004.
International Diabetes Federation. IDF Diabetes. 7th ed. Brussels: International Diabetes Federation; 2015. http://​www.​diabetesatlas.​org.
International Diabetes Federation. IDF Diabetes. 1st ed. Brussels: International Diabetes Federation; 2000. http://​www.​diabetesatlas.​org.
Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes – Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–53. CrossRefPubMed
West KM. Standardization of definition, classification, and reporting in diabetes-related epidemiologic studies. Diabetes Care. 1979;2:65–76. CrossRefPubMed
Zimmet P, Alberti KG, Magliano DJ, Bennett PH. Diabetes mellitus statistics on prevalence and mortality: facts and fallacies. Nature Rev Endocrinol. 2016. doi: 10.​1038/​nrendo.​2016.​105. Published online: 08 July 2016.
Houechanou YCN, Lacroix P, Mizehoun GC, Preux PM, Marin B, Houinato DS. Magnitude of cardiovascular risk factors in rural and urban areas in Benin. Findings from a nationwide steps survey. PLoS ONE. 2015;10:1–13. doi: 10.​1371/​journal.​pone.​0126441. e0126441.
Fajans SS, Conn JW. The early recognition of diabetes mellitus. Ann NY Acad Sci. 1959;82:208–18. CrossRefPubMed
Christensen JO, Sandbaek A, Lauritzen T, Borch-Johnsen K. Population-based stepwise screening for unrecognized type 2 diabetes in general practice is ineffective despite reliable algorithms. Diabetologia. 2004;47:1566–73. CrossRefPubMed
Davies J, Yudkin JS, Atun R. Liberating data: the crucial weapon in the fight against NCDs. Lancet Diabetes Endocrinol. 2016;4:197–98. CrossRefPubMed
GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385:117–71. CrossRef
Zimmet P. Epidemiology of diabetes and its macrovascular manifestations in pacific populations: the medical effects of social progress. Diabetes Care. 1979;2:144–53. CrossRefPubMed
Dowse GK, Gareeboo H, Zimmet PZ, et al. High prevalence of NIDDM impaired glucose tolerance in Indian, creole, and Chinese Mauritians. Diabetes. 1990;39:390–6. CrossRefPubMed
Prior IAM, Rose BS, Davidson F. Metabolic Maladies in New Zealand Maoris. Brit Med J. 1964;1:1065–9. CrossRefPubMedPubMedCentral
Bennett PH, Burch TA, Miller M. Diabetes Mellitus in American (PIMA) Indians. Lancet. 1971;298:125–8. CrossRef
Wise PH, Edwards FM, Thomas DW, Elliott RB, Hatcher L, Craig R. Hyperglycaemia in the Urbanized Aboriginal. The Davenport Study. Med J Aust. 1970;2:1001–6. PubMed
Zimmet P, Taft P, Guinea A, Guthrie W, Thoma K. The high prevalence of diabetes mellitus on a central pacific island. Diabetologia. 1977;13:111–5. CrossRefPubMed
Soderberg S, Zimmet P, Tuomilehto J, et al. Increasing prevalence of type 2 diabetes mellitus in all ethnic groups in Mauritius. Diabetic Med. 2005;22:61–8. CrossRefPubMed
Magliano DJ, Soderberg S, Zimmet PZ, et al. Explaining the increase of diabetes prevalence and plasma glucose in Mauritius. Diabetes Care. 2012;35:87–91. CrossRefPubMed
Ramachandran A, Mary S, Yamuna A, Murugesan N, Snehalatha C. High prevalence of diabetes and cardiovascular risk factors associated with urbanization in India. Diabetes Care. 2008;31:893–8. CrossRefPubMed
Yang WY, Lu JM, Weng JP, et al. Prevalence of diabetes among Men and women in China. N Engl J Med. 2010;362:1090–101. CrossRefPubMed
Satman I, Yilmaz T, Sengul A, et al. Population-based study of diabetes and risk characteristics in Turkey. Results of the Turkish Epidemiology Study (TURDEP). Diabetes Care. 2002;25:1551–6. CrossRefPubMed
Guest CS, O’Dea K. Diabetes in Aborigines and other Australian populations. Aust J Public Health. 1992;16:340–9. CrossRefPubMed
Hoy WE. Kidney disease in Aboriginal Australians: a perspective from the Northern Territory. Clin Kidney J. 2014;7:524–30. CrossRefPubMedPubMedCentral
Mathers M. Dialysis in Central Australia. Current Issues in Indigenous Affairs U3A Hawthorn. 2012. p. 1–7.
Rowley KG, O’Dea K. Diabetes in Australian Aboriginal and Torres Strait Islander peoples. PNG Med J. 2001;44:164–70.
Dunstan DW, Zimmet PZ, Welborn TA, et al. The rising prevalence of diabetes and impaired glucose tolerance. The Australian diabetes, obesity and lifestyle study. Diabetes Care. 2002;25:829–34. CrossRefPubMed
Cameron AJ, Welborn TA, Zimmet PZ, et al. Overweight and obesity in Australia: the 1999–2000 Australian Diabetes, Obesity and Lifestyle Study (AusDiab). Med J Aust. 2003;178:427–32. PubMed
Huang ES, Basu A, O’Grady M, Capretta JC. Projecting the future diabetes population size and related costs for the U.S. Diabetes Care. 2009;32:2225–9. CrossRefPubMedPubMedCentral
Khambalia A, Phongsavan P, Smith BJ, et al. Prevalence and risk factors of diabetes and impaired fasting glucose in Nauru. BMC Public Health. 2011;11:719. CrossRefPubMedPubMedCentral
Franco M, Bilal U, Ordunez P, et al. Population-wide weight loss and regain in relation to diabetes burden and cardiovascular mortality in Cuba 1980–2010: repeated cross sectional surveys and ecological comparison of secular trends. BMJ. 2013;346:f1515. CrossRefPubMed
King H, Finch C, Collins A, et al. Glucose tolerance in Papua New Guinea: ethnic differences, association with environmental and behavioural factors and the possible emergence of glucose intolerance in a highland community. Med J Aust. 1989;51:204–10.
O’Dea K. Marked improvement in carbohydrate and lipid metabolism in diabetic Australian aborigines after temporary reversion to traditional lifestyle. Diabetes. 1984;33:596–603. CrossRefPubMed
Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343–50. CrossRefPubMed
Koestler A. The call girls. London and Sydney: Pan Books; 1976.
Barker DJP. Maternal nutrition, fetal nutrition, and disease in later life. Nutrition. 1997;13:807–13. CrossRefPubMed
Ravelli ACJ, van der Meulen JHP, Michels RPJ, et al. Glucose tolerance in adults after prenatal exposure to famine. Lancet. 1998;351:173–7. CrossRefPubMed
DiKotter F. Mao’s great famine. The history of China’s most devastating catastrophe. 1958–1962. USA: Bloomsberg Publishing; 2010.
Li YP, He YN, Qi L, et al. Exposure to the Chinese famine in early life and the risk of hyperglycemia and type 2 diabetes in adulthood. Diabetes Care. 2010;59:2400–6. CrossRef
Xu Y, Wang L, He J, 2010 China Noncommunicable Disease Surveillance Group, et al. Prevalence and control of diabetes in Chinese adults. JAMA. 2013;310:948–59. CrossRefPubMed
Soh SE, Tint MT, Gluckman PD, et al. Cohort profile: Growing Up in Singapore Towards healthy Outcomes (GUSTO) birth cohort study. Int J Epidemiol. 2014;43:1401–9. CrossRefPubMed
Gluckman P, Hanson M. MisMatch. Why our world no longer fits our bodies. Oxford: Oxford University Press; 2008.
Lumey LH, Khalangot MD, Vaiseman AM. Association between type 2 diabetes and prenatal exposure to the Ukraine famine of 1932–33: a retrospective cohort study. Lancet Diabetes Endocrinol. 2015;3:787–94. CrossRefPubMed
King H, Keuky L, Seng S, Khun T, Roglic G, Pinget M. Diabetes and associated disorders in Cambodia: two epidemiological surveys. Lancet. 2005;366:1633–9. CrossRefPubMed
Zimmet PZ, Magliano DJ, Herman WH, Shaw JE. Diabetes: a 21st century challenge. Lancet Diabetes Endocrinol. 2014;2:56–64. CrossRefPubMed
Zhang P, Zhang XZ, Brown J, et al. Global healthcare expenditure on diabetes for 2010 and 2030. Diab Res Clin Pract. 2010;87:293–301. CrossRef

Novel clinical evidence in continuous glucose monitoring

Novel clinical evidence in continuous glucose monitoring

How real-world studies complement randomized controlled trials

Jean-Pierre Riveline uses data from real-life continuous glucose monitoring studies to illustrate how these can uncover critical information about clinical outcomes that are hard to assess in randomized controlled trials.

This video has been developed through unrestricted educational funding from Abbott Diabetes Care.

Watch the video